Outlook Therapeutics, Inc. (OTLK) Income Statement
OTLK FY2025 at a glance
Fiscal year ended September 30, 2025 · U.S. dollarsOTLK revenue and net income
Where OTLK's revenue goes
FY2025Each bar shows an amount and its share of revenue. OTLK kept −4,416.2% of revenue as net income.
OTLK profit margins
OTLK growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +730.9% | — | −24.7% | −12.2% |
| Gross profit | — | — | — | −18.7% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
OTLK quarterly EPS vs estimates
Outlook Therapeutics beat the analyst EPS estimate in 3 of the last 8 quarters.
OTLK income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $170,124 | $0 | $0 | $0 | $5.9M | $8.1M | $3.1M | $3.8M | $3.0M |
| Cost of revenue | $756,330 | $113,859 | $44,188 | $204,694 | $262,139 | $554,069 | $23.8M | $18.5M | $23.8M | $32,763 |
| Gross profit | $657,205 | −$113,859 | −$44,188 | −$204,694 | −$262,139 | −$554,069 | −$15.7M | $3.1M | $3.8M | $2.9M |
| Research & development | $27.8M | $41.8M | $26.5M | $42.3M | $39.0M | $26.3M | $23.8M | $18.5M | $23.8M | $32.8M |
| Sales, general & admin | $39.9M | $29.9M | $26.7M | $20.7M | $13.0M | $10.0M | $13.2M | $14.2M | $15.9M | $21.6M |
| Total operating expenses | $67.7M | $71.7M | $53.1M | $62.9M | $51.7M | $34.4M | $44.4M | $32.7M | $39.7M | $21.6M |
| Operating income | −$67.1M | −$71.7M | −$53.1M | −$63.1M | −$51.7M | −$35.0M | −$36.3M | −$29.6M | −$35.9M | −$51.3M |
| Interest income | $89,738 | $906,150 | $971,480 | — | — | — | $3.5M | $3.9M | $5.6M | $1.9M |
| Interest expense | $283,128 | $3.2M | $2.5M | $1.5M | $936,127 | $1.8M | $3.5M | $3.9M | $5.6M | $1.9M |
| Income before taxes | −$64.0M | −$75.4M | −$59.0M | −$66.0M | −$53.2M | −$38.5M | −$37.9M | −$33.7M | −$38.3M | −$53.2M |
| Income taxes | −$1.6M | $2,800 | $2,800 | $2,800 | $2,000 | −$3.3M | −$3.4M | −$3.6M | $501,500 | $103,000 |
| Net income | −$62.4M | −$75.4M | −$59.0M | −$66.1M | −$53.2M | −$35.2M | −$34.5M | −$30.1M | −$38.8M | −$53.3M |
| EBITDA | −$63.6M | −$72.1M | −$56.4M | −$64.4M | −$52.0M | −$34.4M | −$31.1M | −$26.8M | −$30.0M | −$49.0M |
| EPS (diluted) | −$0.40 | −$4.10 | −$3.54 | −$3.47 | −$7.00 | −$10.53 | −$38.58 | −$86.00 | −$287.63 | −$263.52 |
| Gross margin | 46.5% | −66.9% | — | — | — | −9.5% | −192.2% | 99.4% | 99.4% | 98.9% |
| Operating margin | −4,744.3% | −42,147.6% | — | — | — | −597.4% | −445.6% | −960.0% | −941.2% | −1,723.1% |
| Net margin | −4,416.2% | −44,301.0% | — | — | — | −602.0% | −423.8% | −974.5% | −1,019.1% | −1,788.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9,000 | $127,439 | $0 | $0 | $1.5M | $0 | $170,124 | $170,124 | $0 | $0 | $0 | $0 |
| Cost of revenue | $17,000 | $149,327 | $29,626 | $916,515 | $439,815 | $29,102 | $28,801 | $28,797 | $28,672 | $28,195 | $28,195 | $11,217 |
| Gross profit | −$8,000 | −$21,888 | −$1.2M | −$1.0M | $1.1M | −$29,102 | −$28,801 | −$28,797 | −$28,672 | −$28,195 | −$28,195 | −$11,217 |
| Research & development | $3.3M | $4.5M | $3.6M | $6.0M | $7.1M | $4.4M | $9.7M | $12.5M | $11.2M | $13.5M | $4.5M | $4.9M |
| Sales, general & admin | $7.6M | $9.5M | $8.6M | $10.3M | $9.7M | $8.0M | $11.9M | $10.4M | $8.4M | $5.4M | $5.8M | $7.5M |
| Total operating expenses | $10.8M | $14.0M | $12.2M | $16.3M | $16.8M | $12.4M | $21.6M | $22.8M | $19.6M | $18.9M | $10.3M | $12.5M |
| Operating income | −$10.8M | −$14.0M | −$13.5M | −$17.3M | −$15.7M | −$12.4M | −$21.6M | −$22.9M | −$19.6M | −$18.9M | −$10.3M | −$12.5M |
| Interest income | — | — | $0 | — | — | — | $48,881 | $239,951 | $404,593 | — | — | — |
| Interest expense | — | $3.0M | — | $264,156 | $49,351 | $18,502 | — | $72.93B | $0 | $3.1M | $2.14T | $2.14T |
| Income before taxes | −$20.3M | −$4.5M | −$23.1M | −$14.8M | −$20.2M | −$46.4M | $17.4M | $5.7M | $44.4M | −$114.3M | −$11.2M | −$13.0M |
| Income taxes | $41,000 | — | — | −$1.6M | — | $2,800 | $17.38T | — | −$2 | $2,800 | −$135,335 | $2.80B |
| Net income | −$20.3M | −$4.5M | −$23.1M | −$13.3M | −$20.2M | −$46.4M | $17.4M | $5.7M | $44.4M | −$114.3M | −$11.2M | −$13.0M |
| EBITDA | −$20.3M | −$14.0M | −$13.5M | −$14.6M | −$20.1M | −$12.4M | −$21.6M | −$22.8M | −$19.5M | −$18.9M | −$10.3M | −$16.7M |
| EPS (diluted) | −$0.09 | −$0.17 | −$0.22 | −$0.28 | −$0.44 | −$0.40 | $0.72 | −$0.94 | −$0.83 | −$1.55 | −$0.78 | −$0.05 |
| Gross margin | −88.9% | −17.2% | — | — | 70.8% | — | −16.9% | −16.9% | — | — | — | — |
| Operating margin | −120,111.1% | −11,006.8% | — | — | −1,046.2% | — | −12,700.6% | −13,447.5% | — | — | — | — |
| Net margin | −225,766.7% | −3,494.3% | — | — | −1,338.8% | — | 10,214.9% | 3,345.4% | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in OTLK's financial statements (latest annual report filed December 19, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
OTLK financial results
In fiscal year 2025 (ended September 30, 2025), Outlook Therapeutics reported revenue of $1.4 million, up 730.9% from the year before. It had a net loss of $62.4 million, a net profit margin of −4,416.2%. Diluted earnings per share came to −$0.40. Over five years revenue grew at an average rate of −24.7% a year.
See the OTLK stock overview for the latest quote and news, or the OTLK chart for price history and technical indicators.
OTLK income statement FAQ
What is Outlook Therapeutics's annual revenue?
Outlook Therapeutics reported total revenue of $1.4 million for fiscal year 2025, which ended on September 30, 2025. That was up 730.9% from $0.2 million the previous year.
Is Outlook Therapeutics profitable?
No. Outlook Therapeutics reported a net loss of $62.4 million in fiscal 2025, a net profit margin of −4,416.2%; its operating margin was −4,744.3%.
What is Outlook Therapeutics's gross margin?
Outlook Therapeutics's gross margin was 46.5% in fiscal 2025: for every $100 of revenue, Outlook Therapeutics kept $46 after the direct cost of its products and services.
How much does Outlook Therapeutics spend on research and development?
Outlook Therapeutics spent $27.8 million on research and development in fiscal 2025, 1,965.3% of revenue.
How fast is Outlook Therapeutics growing?
Revenue grew −24.7% a year on average over the last five fiscal years, from $5.9 million to $1.4 million.
What are Outlook Therapeutics's earnings per share?
Outlook Therapeutics earned $-0.40 per diluted share in fiscal 2025, compared with $-4.10 a year earlier.
When does Outlook Therapeutics's fiscal year end?
Outlook Therapeutics's fiscal year ends in September. The latest annual report covers the year ended September 30, 2025 and was filed on December 19, 2025.